<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Microscopic (lymphocytic and collagenous) colitis: Clinical manifestations, diagnosis, and management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Microscopic (lymphocytic and collagenous) colitis: Clinical manifestations, diagnosis, and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Microscopic (lymphocytic and collagenous) colitis: Clinical manifestations, diagnosis, and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christoph F Dietrich, MD, MBA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Thomas Lamont, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Microscopic colitis is a chronic inflammatory disease of the colon that is characterized by chronic, watery, non-bloody diarrhea. It typically occurs in middle-aged patients and has a female preponderance. The colon appears typically normal or almost normal on colonoscopy in patients with microscopic colitis. The diagnosis is established by biopsy of the colonic mucosa demonstrating characteristic histologic changes. Microscopic colitis, first described in 1980 [<a href="#rid1">1</a>],<strong> </strong>has two main histologic subtypes, lymphocytic colitis, more specifically defined in 1989 [<a href="#rid2">2</a>], and collagenous colitis.</p><p>This topic will review the clinical manifestations, diagnosis, and management of microscopic colitis. Our recommendations are largely consistent with the American Gastroenterological Association Institute guidelines on the management of microscopic colitis [<a href="#rid3">3</a>] and the European guidelines on microscopic colitis [<a href="#rid4">4</a>]. The clinical manifestations, diagnosis, and management of the classic inflammatory bowel disease including ulcerative colitis and Crohn disease are discussed in detail, separately. (See  <a class="medical medical_review" href="/d/html/4067.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults"</a> and  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis"</a> and  <a class="medical medical_review" href="/d/html/4068.html" rel="external">"Management of the hospitalized adult patient with severe ulcerative colitis"</a> and  <a class="medical medical_review" href="/d/html/4070.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults"</a> and  <a class="medical medical_review" href="/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults"</a> and  <a class="medical medical_review" href="/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults"</a>.)</p><p class="headingAnchor" id="H3535518631"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H1121420139"><span class="h2">Incidence and prevalence</span><span class="headingEndMark"> — </span>The estimated incidence of collagenous colitis and lymphocytic colitis are 2.0 to 10.8 and 2.3 to 16 per 100,000 per year, respectively, with higher incidence in northern Europe and northern parts of North America [<a href="#rid5">5-12</a>]. The increasing incidence has reached a plateau [<a href="#rid13">13,14</a>]. The median age at diagnosis of microscopic colitis is approximately 65 years [<a href="#rid15">15</a>]. Approximately 25 percent of patients with microscopic colitis are diagnosed before the age of 45 years. Although microscopic colitis has been reported in children, it is rare [<a href="#rid16">16-18</a>]. Microscopic colitis has a higher incidence in women [<a href="#rid6">6-10,19-32</a>], in the range of 52 to 86 percent [<a href="#rid4">4</a>]. Female preponderance appears to be more pronounced in collagenous as compared with lymphocytic colitis (female-to-male incidence rate ratios, 3.0 and 1.9, respectively) [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H2662792683"><span class="h2">Associated conditions</span><span class="headingEndMark"> — </span>Microscopic colitis has also been associated with several other diseases with autoimmune background (eg, autoimmune thyroiditis, type 1 diabetes mellitus, and nonerosive, oligoarticular arthritis) [<a href="#rid33">33-38</a>]. In one report, concomitant autoimmune diseases were more common in patients with collagenous colitis as compared with lymphocytic colitis (53 versus 26 percent) [<a href="#rid35">35</a>]. Whether these associations reflect an autoimmune pathogenesis of microscopic colitis is unclear.</p><p>The HLA-DR3-DQ2 haplotype that predisposes to celiac disease is also associated with microscopic colitis [<a href="#rid39">39,40</a>]. Microscopic colitis demonstrates a T helper type 1 mucosal cytokine response pattern with upregulated interferon gamma and interleukin-15, tumor necrosis factor, and nitric oxide synthase, a pattern similar to that in celiac disease [<a href="#rid41">41</a>]. While patients with celiac disease have an increased risk of microscopic colitis, limited data suggest that the prevalence of celiac disease is relatively low among patients with microscopic colitis [<a href="#rid42">42-51</a>]. </p><p>The prevalence of celiac disease-like changes in the small bowel of patients with microscopic colitis ranges from 2 to 9 percent. (See  <a class="medical medical_review" href="/d/html/5899.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in children", section on 'High-risk groups'</a>.)</p><p>In rare cases, concurrent microscopic colitis has been reported in patients with inflammatory bowel disease, especially with ulcerative colitis, or vice versa [<a href="#rid52">52</a>]. Patients with microscopic colitis may be at increased risk for acute pancreatitis. In a population-based study of 12,140 patients with microscopic colitis and 57,806 matched controls, there was an increased risk of acute pancreatitis unrelated to gallstones (aHR 2.0, 95% CI 1.6-2.5), but not for gallstone-related acute pancreatitis [<a href="#rid53">53</a>]. Patients with microscopic colitis with a follow-up &gt;10 years continued to have an increase in risk of acute pancreatitis (aHR 1.8, 95% CI 1.1-2.7). In sensitivity analyses, there was an increase in risk of acute pancreatitis in patients with microscopic colitis treated with <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> as compared with matched controls (1.8, 95% CI 1.4-2.5). Whether the increase in incidence of acute pancreatitis in patients with microscopic colitis was due to the presence of active disease or a side effect of budesonide is unclear. Information regarding disease activity and lifestyle factors associated with an increased risk of acute pancreatitis were lacking.</p><p>There are also case reports of concurrent lymphocytic and collagenous gastritis in patients with microscopic colitis [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/d/html/4072.html" rel="external">"Endoscopic diagnosis of inflammatory bowel disease in adults", section on 'Differentiating ulcerative colitis from Crohn disease'</a> and  <a class="medical medical_review" href="/d/html/4072.html" rel="external">"Endoscopic diagnosis of inflammatory bowel disease in adults"</a>.)</p><p class="headingAnchor" id="H973555865"><span class="h1">ETIOLOGY AND RISK FACTORS</span></p><p class="headingAnchor" id="H8"><span class="h2">Medications</span><span class="headingEndMark"> — </span>Nonsteroidal anti-inflammatory drugs (NSAIDs) have been implicated as being causative or triggering flares of microscopic colitis [<a href="#rid55">55-58</a>]. Several other drugs have also been implicated as potential causes of microscopic colitis, including proton pump inhibitors (PPIs), specifically <a class="drug drug_general" data-topicid="9546" href="/d/drug information/9546.html" rel="external">lansoprazole</a>, statins, selective serotonin reuptake inhibitors, histamine H2-receptor antagonists, and other drugs (eg, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>) [<a href="#rid59">59-61</a>]. Concomitant use of PPIs and NSAIDs may increase the risk even further [<a href="#rid62">62</a>]  (<a class="graphic graphic_table graphicRef96937" href="/d/graphic/96937.html" rel="external">table 1</a>). However, convincing pathophysiologic evidence is still lacking, and most of the drugs that have been associated with microscopic colitis are also known to be associated with the development of chronic diarrhea as a side effect [<a href="#rid55">55,62-74</a>].</p><p class="headingAnchor" id="H2199622969"><span class="h2">Smoking</span><span class="headingEndMark"> — </span>Smoking may play a role in the development of microscopic colitis and the clinical outcome [<a href="#rid75">75-77</a>]. In a case-control study that included 340 patients with microscopic colitis, cigarette smoking (past or present) was associated with a significantly increased risk of microscopic colitis (odds ratio 2.1, 95% CI 1.6-2.9) [<a href="#rid78">78-82</a>]. On average, smokers also develop microscopic colitis more than 10 years earlier than non-smokers [<a href="#rid79">79,80</a>].</p><p class="headingAnchor" id="H973555959"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The pathogenesis of microscopic colitis is unclear; however, it is likely to be multifactorial, involving mucosal immune responses to luminal factors in a genetically predisposed individual [<a href="#rid21">21-26</a>]. Although lymphocytic and collagenous colitis have a similar inflammatory cell response, it is uncertain whether they are related colitides [<a href="#rid19">19,20,30,83</a>]. </p><p class="headingAnchor" id="H1304045379"><span class="h2">Pathogenesis of microscopic colitis</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic susceptibility</strong> – It is unclear to what extent a genetic predisposition is associated with the development of microscopic colitis. However, familial cases have been described [<a href="#rid27">27-29</a>]. Interestingly, different members of the same family developed either lymphocytic or collagenous colitis, supporting a similar underlying pathophysiology. Studies have also demonstrated an association between microscopic colitis and HLA-DQ2 or DQ1,3, as well as a higher frequency of HLA-DR3DQ2 haplotype and tumor necrosis factor 2 allele carriage in microscopic colitis, as compared with controls [<a href="#rid39">39,40,84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abnormal collagen metabolism</strong> ‒ Abnormal collagen metabolism may be responsible for the thick collagen band in collagenous colitis. The prominent subepithelial matrix deposition has been attributed to increased expression of the main fibrogenic genes, procollagen I and metalloproteinase inhibitor (TIMP-1), by myofibroblastic cells and inadequate fibrinolysis [<a href="#rid85">85-88</a>]. Patients with collagenous colitis also have increased expression of transforming growth factor (TGF) beta-1, which has been associated with the accumulation of collagen in tissues [<a href="#rid88">88</a>]. TGF beta-1 and vascular endothelial growth factor may influence the balance of local fibrogenesis and fibrinolysis, leading to a net accumulation of immature subepithelial matrix [<a href="#rid89">89,90</a>]. The modification of collagen metabolism has also been explained by the expression of endogenous histamine, prostaglandins, and/or nitric oxide (NO). Increased transcriptional activity of nuclear factor kappa B causes upregulation of inducible NO synthase activity and, subsequently, increased production of NO in the colonic epithelium, which might be a direct cause of secretory diarrhea in patients with collagenous colitis [<a href="#rid91">91</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Altered epithelial barrier function</strong> ‒ An alternative hypothesis is that a defect in epithelial barrier function and luminal factors may lead to an increased transmucosal permeability of antigens and bacteria, leading to immune dysregulation and intestinal inflammation seen in microscopic colitis [<a href="#rid92">92</a>].</p><p></p><p class="bulletIndent1">Synchronous collagenous and pseudomembranous colitis have also been described in some patients, suggesting a possible etiologic role for <em>C.</em> <em>difficile</em> [<a href="#rid93">93-95</a>]. Infection with <em>Yersinia</em> has also been suggested as an inciting event for collagenous colitis [<a href="#rid96">96</a>]. Furthermore, resolution of collagenous colitis has been described following treatment for <em>Helicobacter pylori</em>, but the association remains unclear [<a href="#rid97">97</a>]. A role for bacteria in the pathogenesis of this disorder is also supported by the observation that symptoms and histology can improve in patients with lymphocytic colitis after treatment with bismuth. However, this hypothesis is not supported by the finding that local immunosuppressive treatment with <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> is very efficient in microscopic colitis.</p><p></p><p class="headingAnchor" id="H973562556"><span class="h2">Mechanism of diarrhea</span><span class="headingEndMark"> — </span>Diarrhea in microscopic colitis is likely caused by mucosal inflammation [<a href="#rid20">20,30,98</a>]. The severity of diarrhea correlates with the inflammatory changes in the lamina propria and not with collagen band thickening. Colonic perfusion studies have demonstrated that secretory diarrhea in microscopic colitis results from decreased absorption of sodium chloride, accompanied by a component of active chloride secretion [<a href="#rid20">20,99</a>]. The subepithelial collagenous band plausibly may act as a diffusion barrier. Down-regulation of tight junction molecules, but not epithelial apoptosis, is a structural correlate of barrier dysfunction that contributes to diarrhea by a leak flux mechanism [<a href="#rid99">99</a>]. The observation that fasting can reduce stool volume in microscopic colitis suggests that the diarrhea in microscopic colitis also has an osmotic component [<a href="#rid100">100</a>].</p><p>Concurrent bile acid malabsorption frequently coexists in patients with collagenous colitis. The cause of bile acid malabsorption in patients with microscopic colitis is unclear since morphologic alterations in the terminal ileum are usually absent [<a href="#rid15">15,101</a>].</p><p class="headingAnchor" id="H12"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H3268758125"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>Microscopic colitis is characterized by chronic, non-bloody, watery diarrhea [<a href="#rid15">15,19,21,102</a>]. The onset of diarrhea is often insidious, but sudden onset was reported in approximately 40 percent of patients [<a href="#rid15">15</a>]. Patients with microscopic colitis usually have between four and nine watery stools per day, but in rare cases, bowel movements can exceed 15 or up to 2 liters per day [<a href="#rid15">15,103</a>]. Patients may have associated fecal urgency (70 percent), incontinence (40 percent), and nocturnal episodes (50 percent). Abdominal pain occurs in up to 50 percent of patients with active microscopic colitis (≥3 stools or ≥1 watery stool per day) [<a href="#rid104">104,105</a>]. Patients may have associated weight loss due to fluid loss or decreased oral intake. Extraintestinal symptoms, such as arthralgia, arthritis, or uveitis can occur. The quality of life is reduced [<a href="#rid106">106</a>]. (See <a class="local">'Associated conditions'</a> above.)</p><p>Collagenous colitis seems to be a more severe type of bowel inflammation and lymphocytic colitis tends to occur earlier in life [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>Laboratory findings in microscopic colitis are generally nonspecific. Mild anemia, elevated erythrocyte sedimentation rate, and autoantibodies are found in approximately one-half of patients [<a href="#rid15">15,36,107-109</a>]. These autoantibodies include rheumatoid factor, antinuclear and antimitochondrial antibodies, antineutrophilic cytoplasmic antibodies, anti-<em>Saccharomyces cerevisiae</em> antibodies, and antithyroid peroxidase antibodies. In rare cases, patients may have a protein-losing enteropathy and associated hypoalbuminemia. (See  <a class="medical medical_review" href="/d/html/4769.html" rel="external">"Protein-losing gastroenteropathy", section on 'Clinical features'</a>.)</p><p>Increased levels of the inflammatory markers, eosinophil protein X, myeloperoxidase, and tryptase, have been detected in stool from patients with collagenous colitis [<a href="#rid110">110</a>]. Studies that have evaluated fecal calprotectin excretion as a marker of active microscopic colitis have been conflicting [<a href="#rid111">111,112</a>]. Additional studies are needed to validate these findings and to clarify the role of fecal markers in the diagnosis and management of microscopic colitis.</p><p class="headingAnchor" id="H15"><span class="h1">DIAGNOSTIC APPROACH</span></p><p class="headingAnchor" id="H2001234132"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>Microscopic colitis should be suspected in patients with chronic diarrhea, particularly in middle-aged and older adults. The diagnosis of microscopic colitis is established by biopsy of the colonic mucosa demonstrating characteristic histologic changes. (See <a class="local">'Endoscopy and biopsy'</a> below.)</p><p class="headingAnchor" id="H3288996471"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>Evaluation of a patient with suspected microscopic colitis serves to exclude other causes of diarrhea and establish the diagnosis of microscopic colitis [<a href="#rid113">113,114</a>]. </p><p class="headingAnchor" id="H973560190"><span class="h3">Laboratory studies</span><span class="headingEndMark"> — </span>Stool studies should include stool <em>Clostridioides difficile</em> toxin, routine stool cultures (<em>Salmonella, Shigella, Campylobacter, Yersinia</em>), and specific testing for <em>Escherichia coli O157:H7</em>. Microscopy for ova and parasites (three samples) and a <em>Giardia</em> stool antigen test should also be performed, particularly if the patient has risk factors such as recent travel to endemic areas. We perform celiac serologies to exclude celiac sprue. In addition, a complete blood count, electrolytes, and albumin should be obtained as patients with microscopic colitis may have mild anemia and, in rare cases, a protein-losing enteropathy. The use of calprotectin to exclude or monitor microscopic colitis is not recommended [<a href="#rid4">4,115,116</a>]. (See <a class="local">'Laboratory findings'</a> above.)</p><p class="headingAnchor" id="H973560197"><span class="h3">Endoscopy and biopsy</span><span class="headingEndMark"> — </span>Endoscopic evaluation of the colon with mucosal biopsies is necessary to establish the diagnosis of microscopic colitis [<a href="#rid33">33</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of procedure </strong>– We perform colonoscopy with separate sampling at least of the right and left colon. Colonoscopy is generally safe in patients with microscopic colitis. Perforations have been reported in patients with significant collagen deposits ("fractured colon"), but are rare [<a href="#rid117">117-119</a>]. The rationale for performing colonoscopy rather than a more limited evaluation of the left colon with flexible sigmoidoscopy is that microscopic colitis can be patchy. In addition, the severity of histologic changes declines from the proximal to the distal colon. However, flexible sigmoidoscopy (rectum is not sufficient), will diagnose more than 90 percent of microscopic colitis [<a href="#rid120">120-122</a>]. </p><p></p><p class="bulletIndent1">In small case series, chromoendoscopy using <a class="drug drug_general" data-topicid="9088" href="/d/drug information/9088.html" rel="external">indigo carmine</a> has been used to highlight mucosal alterations that correspond to the histological distribution of microscopic colitis [<a href="#rid123">123</a>]. However, larger studies are needed before routine use of chromoendoscopy can be recommended for the diagnosis of microscopic colitis. Confocal laser endomicroscopy is a promising endoscopic tool but its specific role in diagnosing microscopic colitis has to be determined [<a href="#rid124">124</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endoscopic findings</strong> – The endoscopic appearance of the colon is typically normal. Macroscopic features can include slight edema, erythema, friability, exudative lesions, and scars [<a href="#rid33">33,125</a>]. However, there is significant inter-observer variability among endoscopists [<a href="#rid126">126,127</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histology</strong> – The inflammatory cell response is similar in lymphocytic and collagenous colitis, consisting mainly of mononuclear infiltrates, with few neutrophils and eosinophils in the lamina propria  (<a class="graphic graphic_picture graphicRef54897" href="/d/graphic/54897.html" rel="external">picture 1</a>). However, there are certain key histologic features that are used to diagnose collagenous and lymphocytic colitis  (<a class="graphic graphic_table graphicRef96938" href="/d/graphic/96938.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Collagenous colitis </strong>– Collagenous colitis is characterized by a colonic subepithelial collagen band ≥10 micrometers in diameter  (<a class="graphic graphic_diagnosticimage graphicRef79824" href="/d/graphic/79824.html" rel="external">image 1</a> and <a class="graphic graphic_picture graphicRef60570 graphicRef74390" href="/d/graphic/60570.html" rel="external">picture 2A-B</a>) [<a href="#rid20">20</a>]. The band is most evident between the crypts. While assessing the thickness of the collagen band, it is important that biopsy specimens are well-oriented and cut perpendicular to the mucosal surface so that the collagen band does not falsely appear to be thickened.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lymphocytic colitis</strong> – Lymphocytic colitis is characterized by ≥20 intraepithelial lymphocytes (IEL) per 100 surface epithelial cells [<a href="#rid19">19</a>]. Crypt architecture is usually not distorted, but focal cryptitis may be present.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Incomplete microscopic colitis or microscopic colitis not otherwise specified (NOS) –</strong> NOS has been used to describe a subgroup of patients with diarrhea, an increase in cellular infiltrate in the colonic lamina propria, and either an abnormal collagenous layer or IELs short of fulfilling the criteria for collagenous colitis and lymphocytic colitis [<a href="#rid128">128</a>]. However, it is unclear if this represents a separate subtype of microscopic colitis as these findings may be seen in a variety of conditions (eg, adjacent to an adenoma, in ischemic colitis, irritable bowel syndrome, and chronic trauma) [<a href="#rid129">129</a>].</p><p></p><p>Focal areas of histologic findings as typically associated with microscopic colitis have also been described in patients with established inflammatory bowel disease (IBD) [<a href="#rid130">130-134</a>]. However, endoscopic features of IBD are frequently present [<a href="#rid130">130-134</a>]. They may also precede the development of overt clinical and histopathologic evidence of IBD, particularly Crohn disease. (See  <a class="medical medical_review" href="/d/html/4070.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults", section on 'Endoscopy'</a>.)</p><p class="headingAnchor" id="H973560164"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The main considerations in the differential diagnosis of microscopic colitis includes celiac disease, inflammatory bowel disease, and irritable bowel syndrome. These can be differentiated from microscopic colitis by history, laboratory evaluation, and endoscopy with biopsy. Other causes of chronic diarrhea are discussed in detail, separately. (See  <a class="medical medical_review" href="/d/html/2591.html" rel="external">"Approach to the adult with chronic diarrhea in resource-abundant settings", section on 'Initial evaluation'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Celiac disease</strong> – Patients with celiac disease may have similar symptoms of chronic diarrhea but can be distinguished from microscopic colitis by serologic testing and small bowel biopsy. (See  <a class="medical medical_review" href="/d/html/4771.html" rel="external">"Diagnosis of celiac disease in adults", section on 'Diagnostic approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Crohn disease</strong> – Patchy colitis in patients with microscopic colitis can mimic Crohn disease. Characteristic features of Crohn disease such as the presence of perianal disease (fissures, fistulas), chronic transmural inflammation, and granulomas on biopsy are absent in microscopic colitis. </p><p></p><p class="bulletIndent1">It is important to note that focal areas of histologic findings as typically associated with microscopic colitis have also been described in patients with established inflammatory bowel disease (IBD) [<a href="#rid130">130-134</a>]. They may also precede the development of overt clinical and histopathologic evidence of IBD, particularly Crohn disease. However, endoscopic features of IBD are frequently present, providing a clue toward the diagnosis [<a href="#rid130">130-134</a>]. (See  <a class="medical medical_review" href="/d/html/4070.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults", section on 'Endoscopy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Irritable bowel syndrome</strong> – Patients with diarrhea-predominant irritable bowel syndrome (IBS) may present with chronic diarrhea similar to patients with microscopic colitis [<a href="#rid135">135,136</a>]. However, IBS is predominantly characterized by recurrent chronic abdominal pain. The abdominal pain in IBS is often related to defecation and is associated with a change in frequency or consistency (form) of the stools. (See  <a class="medical medical_review" href="/d/html/2630.html" rel="external">"Clinical manifestations and diagnosis of irritable bowel syndrome in adults", section on 'Clinical manifestations'</a>.)</p><p></p><p class="headingAnchor" id="H20"><span class="h1">INITIAL APPROACH</span></p><p class="headingAnchor" id="H2944249853"><span class="h2">Pretreatment evaluation of disease activity</span><span class="headingEndMark"> — </span>The primary goal of management in patients with microscopic colitis is to achieve clinical remission (&lt;3 stools per day and no watery stool during a one-week period) and to improve the patient's quality of life. It is unclear if histologic remission is necessary [<a href="#rid23">23</a>]. Active disease is defined ≥3 stools daily or ≥1 watery stool daily [<a href="#rid137">137</a>].  </p><p class="headingAnchor" id="H4002906924"><span class="h2">General measures in all patients</span></p><p class="headingAnchor" id="H2490739655"><span class="h3">Avoid culprit medications and smoking cessation</span><span class="headingEndMark"> — </span>Patients should be advised to avoid nonsteroidal anti-inflammatory drugs and, if possible, discontinue medications associated with microscopic colitis  (<a class="graphic graphic_table graphicRef96937" href="/d/graphic/96937.html" rel="external">table 1</a>) [<a href="#rid138">138</a>]. (See <a class="local">'Etiology and risk factors'</a> above.)</p><p class="headingAnchor" id="H1285154915"><span class="h3">Antidiarrheals</span><span class="headingEndMark"> — </span>For symptomatic management of diarrhea, we use the antidiarrheal agent, <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">loperamide</a>, particularly at night to decrease the frequency of nocturnal episodes [<a href="#rid139">139</a>]. Antidiarrheals may be used alone in patients with mild diarrhea (&lt;3 stools daily and no watery stool daily) or in conjunction with other therapies, based on the severity of symptoms, but evidence-based studies are lacking.</p><p class="headingAnchor" id="H2546246272"><span class="h2">Glucocorticoids for active disease</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">Budesonide</a> – In patients with active disease (≥3 stools daily or ≥1 watery stool daily) or diarrhea that persists despite the use of antidiarrheals, we recommend the addition of oral budesonide (9 mg daily for six to eight weeks). Budesonide is a locally active corticosteroid with extensive first-pass metabolism in the liver and low systemic exposure [<a href="#rid4">4,140-143</a>]. </p><p></p><p class="bulletIndent1">Incomplete microscopic colitis is a subtype of microscopic colitis. <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">Budesonide</a> is recommended as a first-line treatment for microscopic colitis. Budesonide decreased the frequency of soft or watery stools and improved the patients' quality of life significantly in incomplete microscopic colitis [<a href="#rid144">144</a>].</p><p></p><p class="bulletIndent1">Symptomatic improvement can be seen within a few days. However, complete resolution usually requires six to eight weeks or longer. We continue <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> for at least eight weeks and then gradually taper budesonide in patients in clinical remission (&lt;3 stools daily and no watery stools). We taper oral budesonide to 6 mg for two weeks, followed by 3 mg for another two weeks, and then discontinue therapy. </p><p></p><p class="bulletIndent1">In patients who are not in clinical remission at eight weeks, or if symptoms recur on tapering, the <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> dose of 9 mg can be continued for 12 weeks or longer before tapering the dose.</p><p></p><p class="bulletIndent1">Randomized trials in patients with collagenous colitis suggest that <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> is effective for short-term treatment of microscopic colitis and can improve quality of life [<a href="#rid141">141,145-150</a>]. A meta-analysis of eight randomized trials that included 248 patients randomized to glucocorticoids versus placebo found that short-term clinical response rates were significantly higher with budesonide, as compared with placebo (risk ratio 3.1, 95% CI 2.1-4.6) [<a href="#rid151">151</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">Budesonide</a> has also demonstrated efficacy in inducing clinical and histologic remission in patients with lymphocytic colitis [<a href="#rid152">152</a>]. In a meta-analysis of two randomized trials (only one of which was published) that included 57 patients with lymphocytic colitis assigned to budesonide or placebo, treatment with budesonide resulted in an improvement in diarrhea and microscopic inflammation as compared with placebo (88 versus 38 percent, and 78 versus 33 percent, respectively). In a subsequent randomized trial, 57 patients with active lymphocytic colitis were assigned to budesonide (9 mg daily), mesalazine (3 g daily), or placebo for eight weeks [<a href="#rid140">140</a>]. Clinical and histologic remission rates at week 8 were higher in patients treated with budesonide as compared with placebo (79 versus 42 percent and 68 versus 21 percent, respectively). However, there was no statistically significant difference in clinical remission rates between the <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> and placebo groups (63 versus 42 percent). Rates of drug-related adverse events were not significantly different between the three groups. Of the 27 patients in clinical remission at the end of the eight weeks, seven (26 percent) had a relapse in the 16-week treatment free follow-up. Of note, the study excluded patients with suspected drug-induced lymphocytic colitis and those with mild symptoms. The placebo group had a higher proportion of smokers and a longer duration of symptoms as compared with the treatment groups, both of which may be a source of potential bias, however, these results are consistent with prior studies. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">Prednisone</a> – We reserve the use of prednisone or <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> for the treatment of microscopic colitis in patients in whom <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> therapy is not feasible. While indirect evidence suggests that prednisone should induce clinical remission, its efficacy has not been demonstrated. In addition, systemic glucocorticoids have a higher risk of adverse events. In a randomized clinical trial in which 12 patients with microscopic colitis were assigned to prednisone or placebo for two weeks, there was no difference in the clinical remission rates [<a href="#rid153">153</a>]. Prednisone lead to a reduction in colonic inflammation, but not in the thickness of the collagen band [<a href="#rid16">16,154,155</a>]. As compared with budesonide, prednisone is associated with a lower response rate (53 versus 83 percent), more side effects, and a higher risk of relapse when therapy is withdrawn [<a href="#rid155">155,156</a>].</p><p></p><p class="headingAnchor" id="H4034745087"><span class="h1">SUBSEQUENT APPROACH</span></p><p class="headingAnchor" id="H1689792259"><span class="h2">Mild persistent symptoms despite glucocorticoids</span></p><p class="headingAnchor" id="H1199979446"><span class="h3">Cholestyramine</span><span class="headingEndMark"> — </span>In patients with mild, persistent diarrhea despite <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a>, we use concomitant therapy with <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">loperamide</a> and <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a> (4 g four times per day). In patients with an improvement in diarrhea, we continue cholestyramine until the diarrhea resolves. Cholestyramine is a bile acid binding resin that is used to treat diarrhea that is due to concurrent bile acid malabsorption in patients with microscopic colitis [<a href="#rid101">101</a>]. In a randomized trial, 23 patients with collagenous colitis and 41 with lymphocytic colitis were assigned to <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> at 2.4 g per day alone or in combination with cholestyramine at 4 g per day for six months [<a href="#rid157">157</a>]. Clinical and histologic remission was observed in 91 percent of patients with collagenous colitis and 85 percent of patients with lymphocytic colitis. While the rates of clinical remission were slightly higher in patients with collagenous colitis who were treated with the combination of cholestyramine and mesalamine (100 versus 73 percent), this trial lacked blinding, and there was no placebo group. In addition, part of the measured effect may have been due to spontaneous improvement in microscopic colitis. Cholecystectomy is not associated with microscopic colitis [<a href="#rid158">158</a>]. (See <a class="local">'Mechanism of diarrhea'</a> above.)</p><p class="headingAnchor" id="H4269932222"><span class="h3">Bismuth subsalicylate</span><span class="headingEndMark"> — </span>In patients who fail to respond to a two-week trial of <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a>, we use <a class="drug drug_general" data-topicid="101044" href="/d/drug information/101044.html" rel="external">bismuth subsalicylate</a> (three 262 mg tablets three times daily) [<a href="#rid101">101,159</a>]. However, there are limited data to support bismuth subsalicylate, and its use is controversial [<a href="#rid4">4</a>]. In an open-label study, treatment with bismuth subsalicylate was associated with improvement in symptoms in 11 of 13 patients and resolution of colitis in nine [<a href="#rid159">159</a>]. These results were confirmed in a subsequent preliminary trial in which 14 patients were randomly assigned to receive bismuth subsalicylate (three 262 mg chewable tablets three times daily) or placebo for eight weeks [<a href="#rid160">160</a>]. As compared with placebo, treatment with bismuth was reportedly associated with a significant decrease in fecal frequency and weight, improvement in consistency, and improvement in colonic histology. However, the results of this study have not been published. </p><p class="headingAnchor" id="H36450300"><span class="h2">Non-responders or intolerance to glucocorticoids</span><span class="headingEndMark"> — </span>Approximately 10 to 20 percent of patients treated with <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> are nonresponders [<a href="#rid147">147</a>]. Other treatment approaches may also be required for patients whose symptoms do not respond to budesonide, and for patients who cannot tolerate budesonide, or corticosteroid therapy in general.</p><p class="headingAnchor" id="H1655488102"><span class="h3">Exclude other etiologies in budesonide non-responders</span><span class="headingEndMark"> — </span>Patients with an inadequate response to <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a>, <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a>, antidiarrheals, and/or bismuth should be re-evaluated for other causes of diarrhea (eg, celiac disease, hyperthyroidism, carcinoid syndrome, VIPoma, persistent NSAID use) [<a href="#rid161">161-163</a>]. (See  <a class="medical medical_review" href="/d/html/4771.html" rel="external">"Diagnosis of celiac disease in adults", section on 'Diagnostic approach'</a> and  <a class="medical medical_review" href="/d/html/7847.html" rel="external">"Diagnosis of hyperthyroidism"</a> and  <a class="medical medical_review" href="/d/html/2622.html" rel="external">"Diagnosis of carcinoid syndrome and tumor localization"</a> and  <a class="medical medical_review" href="/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management"</a> and  <a class="medical medical_review" href="/d/html/2570.html" rel="external">"NSAIDs: Adverse effects on the distal small bowel and colon"</a>.)</p><p class="headingAnchor" id="H3996504528"><span class="h3">Biologic agents and immunomodulators</span><span class="headingEndMark"> — </span>In patients with refractory microscopic colitis, we use anti-tumor necrosis factor (TNF) therapy (eg, <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>) or immunomodulators (eg, <a class="drug drug_general" data-topicid="9612" href="/d/drug information/9612.html" rel="external">6-mercaptopurine</a>, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>). Limited evidence from small case series and retrospective studies suggest that anti-TNF agents and immunomodulators can induce remission in patients with refractory microscopic colitis [<a href="#rid164">164-168</a>]. Biologic agents and immunomodulators including <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a> [<a href="#rid169">169-173</a>] could be considered in selected patients with severe symptoms refractory to <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a>. We do not use <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> for the treatment of microscopic colitis. </p><p class="headingAnchor" id="H2285994451"><span class="h3">Surgery for treatment resistant disease</span><span class="headingEndMark"> — </span>Surgery (ileostomy, colectomy) should be reserved for management of microscopic colitis that is refractory to medical therapy [<a href="#rid174">174-177</a>]. Ileostomy may be the procedure of choice in older patients with refractory disease [<a href="#rid176">176</a>].</p><p class="headingAnchor" id="H866027974"><span class="h3">Therapies lacking efficacy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aminosalicylates</strong> ‒ Aminosalicylates including <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> appear to be ineffective in the treatment of collagenous colitis and lymphocytic colitis [<a href="#rid178">178</a>]. In a randomized trial in which 92 patients with active collagenous colitis were assigned to treatment with oral <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> (9 mg daily), mesalamine (3 grams daily), or placebo for eight weeks, remission rates with mesalamine were comparable to placebo (32 and 38 percent, respectively) [<a href="#rid15">15,150</a>]. Maintenance treatment has not been studied. </p><p></p><p class="bulletIndent1">Similarly, in a randomized trial in which 57 patients with active lymphocytic colitis were assigned to treatment with <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a>, <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> (3 grams daily), or placebo for eight weeks, there was no significant difference in clinical and histologic remission rates between mesalamine and placebo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other </strong>– Although a number of other agents (eg, <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>, probiotic <em>E. coli</em> strain Nissle, <em>Boswellia serrata</em> extract, and <em>Lactobacillus acidophilus</em> and Bifidobacterium subspecies) have been used to treat patients with microscopic colitis, they have not been consistently effective [<a href="#rid141">141,142,179-183</a>].</p><p></p><p class="headingAnchor" id="H36449563"><span class="h2">Relapse and maintenance therapy</span><span class="headingEndMark"> — </span>Symptomatic relapse occurs in up to 80 percent of patients after cessation of initial <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> treatment [<a href="#rid145">145</a>]. However, routine maintenance treatment with budesonide in all patients with microscopic colitis is controversial as long-term treatment may increase the risk of steroid-related side effects [<a href="#rid156">156,184</a>]. In patients with relapse following remission we use continuous maintenance therapy at the lowest dose that maintains clinical remission (no more than 6 mg per day then tapered to the lowest effective dose and continued for 6 to 12 months) [<a href="#rid3">3,151,152</a>]. Alternatively patients can either be retreated with intermittent courses (six to eight weeks) of budesonide. (See <a class="local">'Glucocorticoids for active disease'</a> above.)</p><p>Several randomized trials have demonstrated the efficacy of <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> in maintenance of remission in collagenous colitis [<a href="#rid185">185,186</a>]. A pooled analysis included two maintenance budesonide trials with a six-week, open-label induction phase, followed by a six-month, double-blind maintenance phase with either budesonide (6 mg daily) or placebo, in patients with collagenous colitis [<a href="#rid151">151</a>]. In this analysis, long-term treatment with budesonide was significantly superior to placebo for maintenance of clinical response (risk ratio 3.2, 95% CI 1.1-9.9). However, relapse occurred in 46 to 80 percent of patients within six months of treatment cessation. In another trial, budesonide at a mean dose of 4.5 mg per day maintained clinical remission for at least one year in the majority of patients with collagenous colitis and preserved health-related quality of life [<a href="#rid187">187</a>].</p><p>Unlike patients with inflammatory bowel disease, the risk of osteoporosis is not increased in patients with microscopic colitis in the absence of glucocorticoid use. However, patients with active disease requiring long-standing glucocorticoid treatment may require supplementation of calcium and vitamin D [<a href="#rid188">188</a>]. (See  <a class="medical medical_review" href="/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'Calcium and vitamin D'</a>.)</p><p class="headingAnchor" id="H973558070"><span class="h1">NATURAL HISTORY</span><span class="headingEndMark"> — </span>Microscopic colitis has a chronic, intermittent course in most patients [<a href="#rid15">15,189,190</a>]. Diarrhea may resolve within weeks with or without treatment, but relapses are common (approximately 30 to 60 percent) [<a href="#rid23">23,65,145,175</a>]. Few prospective studies have examined the natural history of microscopic colitis in patients who received medical treatment. One of the largest such studies included 37 patients with collagenous and 44 patients with lymphocytic colitis who were followed prospectively after diagnosis for an average of 37 months [<a href="#rid65">65</a>]. Patients were treated with a variety of interventions, including withdrawal of implicated medications and the use of salicylates, <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, and <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a>. These interventions were associated with long-term cessation of diarrhea in approximately 70 percent of patients, while 25 to 30 percent relapsed.</p><p>The long-term course of patients with lymphocytic colitis may be more favorable than with collagenous colitis [<a href="#rid63">63,191</a>]. A retrospective study compared the natural history of 96 patients with collagenous colitis and 80 patients with lymphocytic colitis [<a href="#rid63">63</a>]. Resolution or significant improvement occurred significantly more often in those with lymphocytic colitis, as compared with collagenous colitis (84 versus 74 percent).</p><p>Microscopic colitis has not been associated with an increased risk of colorectal cancer, and transformation between collagenous and lymphocytic colitis is rare [<a href="#rid19">19,191</a>]. </p><p class="headingAnchor" id="H3578458906"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118608.html" rel="external">"Society guideline links: Microscopic colitis"</a>.)</p><p class="headingAnchor" id="H374846607"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/86919.html" rel="external">"Patient education: Microscopic colitis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and clinical presentation </strong>–<strong> </strong>Microscopic colitis is a chronic inflammatory disease of the colon that is characterized by chronic, watery, non-bloody diarrhea. Based on the histologic features, microscopic colitis is divided into collagenous colitis, lymphocytic colitis, and incomplete microscopic colitis. Microscopic colitis has a female preponderance, with a mean age at diagnosis of 65 years. Patients typically present with insidious onset of chronic, non-bloody, watery diarrhea. Associated symptoms include fecal urgency (70 percent), abdominal pain (50 percent), fecal incontinence (40 percent), and nocturnal episodes (50 percent). (See <a class="local">'Epidemiology'</a> above and <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>– The pathogenesis of microscopic colitis is unclear, but it is likely to be multifactorial, involving mucosal immune responses to luminal factors in a genetically predisposed individual. Medications and smoking have been implicated as being causative or triggering flares of microscopic colitis  (<a class="graphic graphic_table graphicRef96937" href="/d/graphic/96937.html" rel="external">table 1</a>). Diarrhea in microscopic colitis is likely caused by mucosal inflammation. However, concurrent bile acid malabsorption frequently coexists in patients with collagenous colitis. (See <a class="local">'Pathophysiology'</a> above and <a class="local">'Etiology and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> –<strong> </strong>Microscopic colitis should be suspected in a patient with chronic diarrhea, particularly in middle-aged and older adults. Evaluation of a patient with suspected microscopic colitis should include stool cultures and a colonoscopy, with mucosal biopsy to establish the diagnosis of microscopic colitis and to exclude other inflammatory diseases. Collagenous colitis is classically characterized by colonic subepithelial collagen band &gt;10 micrometers in thickness. Lymphocytic colitis is characterized by an intraepithelial lymphocytic infiltrate (≥20 lymphocytes per 100 epithelial cells). (See <a class="local">'Diagnostic approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General measures for all patients </strong>– Patients should be advised to avoid nonsteroidal anti-inflammatory drugs and, if possible, discontinue medications associated with microscopic colitis. Antidiarrheals may be used alone in patients with mild diarrhea or in conjunction with other therapies based on the severity of symptoms. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">Budesonide</a><strong> for patients with active disease </strong>– For patients with microscopic colitis with active disease <strong>(≥3 stools daily or ≥1 watery stool daily)</strong>, we recommend budesonide (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). We usually begin with 9 mg per day for six to eight weeks. If the patient is in clinical remission (&lt;3 stools daily and no watery stools), we taper to 6 mg for two weeks, to 3 mg for another two weeks, and then discontinue therapy. If the symptoms are not controlled or if symptoms recur on tapering, the dose of 9 mg can be continued for 12 weeks or longer before tapering budesonide. (See <a class="local">'Initial approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients who fail to respond to </strong><a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> – In patients who do not respond to budesonide, we suggest concomitant therapy with <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). If the combination of budesonide and cholestyramine is not effective, we suggest a trial of <a class="drug drug_general" data-topicid="101044" href="/d/drug information/101044.html" rel="external">bismuth subsalicylate</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We reserve the use of anti-tumor necrosis factor agents for microscopic colitis that is refractory to a combination of budesonide, antidiarrheals, cholestyramine and/or bismuth subsalicylate once other causes of diarrhea have been excluded. We reserve surgery for patients with microscopic colitis that is refractory to medical therapy. (See <a class="local">'Non-responders or intolerance to glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Maintenance therapy in selected patients</strong> – Patients with recurrent symptoms after an initial response to <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> can be retreated with budesonide as maintenance therapy at the lowest dose that maintains clinical remission. (See <a class="local">'Relapse and maintenance therapy'</a> above.)</p><p></p><p><strong>ACKNOWLEDGMENT</strong> — The UpToDate editorial staff acknowledges Paul Rutgeerts, MD (deceased), who contributed as a section editor for UpToDate in Gastroenterology.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Read NW, Krejs GJ, Read MG, et al. Chronic diarrhea of unknown origin. Gastroenterology 1980; 78:264.</a></li><li><a class="nounderline abstract_t">Lazenby AJ, Yardley JH, Giardiello FM, et al. Lymphocytic ("microscopic") colitis: a comparative histopathologic study with particular reference to collagenous colitis. Hum Pathol 1989; 20:18.</a></li><li><a class="nounderline abstract_t">Nguyen GC, Smalley WE, Vege SS, et al. American Gastroenterological Association Institute Guideline on the Medical Management of Microscopic Colitis. Gastroenterology 2016; 150:242.</a></li><li><a class="nounderline abstract_t">Miehlke S, Guagnozzi D, Zabana Y, et al. European guidelines on microscopic colitis: United European Gastroenterology (UEG) and European Microscopic Colitis Group (EMCG) statements and recommendations. United European Gastroenterol J 2020; :2050640620951905.</a></li><li><a class="nounderline abstract_t">Bohr J, Tysk C, Eriksson S, Järnerot G. Collagenous colitis in Orebro, Sweden, an epidemiological study 1984-1993. Gut 1995; 37:394.</a></li><li><a class="nounderline abstract_t">Olesen M, Eriksson S, Bohr J, et al. Microscopic colitis: a common diarrhoeal disease. An epidemiological study in Orebro, Sweden, 1993-1998. Gut 2004; 53:346.</a></li><li><a class="nounderline abstract_t">Fernández-Bañares F, Salas A, Forné M, et al. Incidence of collagenous and lymphocytic colitis: a 5-year population-based study. Am J Gastroenterol 1999; 94:418.</a></li><li><a class="nounderline abstract_t">Agnarsdottir M, Gunnlaugsson O, Orvar KB, et al. Collagenous and lymphocytic colitis in Iceland. Dig Dis Sci 2002; 47:1122.</a></li><li><a class="nounderline abstract_t">Pardi DS, Loftus EV Jr, Smyrk TC, et al. The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut 2007; 56:504.</a></li><li><a class="nounderline abstract_t">Williams JJ, Kaplan GG, Makhija S, et al. Microscopic colitis-defining incidence rates and risk factors: a population-based study. Clin Gastroenterol Hepatol 2008; 6:35.</a></li><li><a class="nounderline abstract_t">Wickbom A, Bohr J, Eriksson S, et al. Stable incidence of collagenous colitis and lymphocytic colitis in Örebro, Sweden, 1999-2008: a continuous epidemiologic study. Inflamm Bowel Dis 2013; 19:2387.</a></li><li><a class="nounderline abstract_t">Bonderup OK, Wigh T, Nielsen GL, et al. The epidemiology of microscopic colitis: a 10-year pathology-based nationwide Danish cohort study. Scand J Gastroenterol 2015; 50:393.</a></li><li><a class="nounderline abstract_t">Tong J, Zheng Q, Zhang C, et al. Incidence, prevalence, and temporal trends of microscopic colitis: a systematic review and meta-analysis. Am J Gastroenterol 2015; 110:265.</a></li><li><a class="nounderline abstract_t">Tong J, Zheng Q, Zhang C, et al. Erratum: Incidence, Prevalence, and Temporal Trends of Microscopic Colitis: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2015; 110:1121.</a></li><li><a class="nounderline abstract_t">Bohr J, Tysk C, Eriksson S, et al. Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients. Gut 1996; 39:846.</a></li><li><a class="nounderline abstract_t">Gremse DA, Boudreaux CW, Manci EA. Collagenous colitis in children. Gastroenterology 1993; 104:906.</a></li><li><a class="nounderline abstract_t">Yardley JH, Lazenby AJ, Kornacki S. Collagenous colitis in children. Gastroenterology 1993; 105:647.</a></li><li><a class="nounderline abstract_t">Józefczuk J, Wozniewicz BM. Clear cell colitis: a form of microscopic colitis in children. World J Gastroenterol 2008; 14:231.</a></li><li><a class="nounderline abstract_t">Veress B, Löfberg R, Bergman L. Microscopic colitis syndrome. Gut 1995; 36:880.</a></li><li><a class="nounderline abstract_t">Lee E, Schiller LR, Vendrell D, et al. Subepithelial collagen table thickness in colon specimens from patients with microscopic colitis and collagenous colitis. Gastroenterology 1992; 103:1790.</a></li><li><a class="nounderline abstract_t">Giardiello FM, Lazenby AJ, Bayless TM. The new colitides, Collagenous, lymphocytic, and diversion colitis. Gastroenterol Clin North Am 1995; 24:717.</a></li><li><a class="nounderline abstract_t">Jessurun J, Yardley JH, Giardiello FM, et al. Chronic colitis with thickening of the subepithelial collagen layer (collagenous colitis): histopathologic findings in 15 patients. Hum Pathol 1987; 18:839.</a></li><li><a class="nounderline abstract_t">Carpenter HA, Tremaine WJ, Batts KP, Czaja AJ. Sequential histologic evaluations in collagenous colitis. Correlations with disease behavior and sampling strategy. Dig Dis Sci 1992; 37:1903.</a></li><li><a class="nounderline abstract_t">Lazenby AJ, Yardley JH, Giardiello FM, Bayless TM. Pitfalls in the diagnosis of collagenous colitis: experience with 75 cases from a registry of collagenous colitis at the Johns Hopkins Hospital. Hum Pathol 1990; 21:905.</a></li><li><a class="nounderline abstract_t">Widgren S, Jlidi R, Cox JN. Collagenous colitis: histologic, morphometric, immunohistochemical and ultrastructural studies. Report of 21 cases. Virchows Arch A Pathol Anat Histopathol 1988; 413:287.</a></li><li><a class="nounderline abstract_t">Zins BJ, Tremaine WJ, Carpenter HA. Collagenous colitis: mucosal biopsies and association with fecal leukocytes. Mayo Clin Proc 1995; 70:430.</a></li><li><a class="nounderline abstract_t">Abdo AA, Zetler PJ, Halparin LS. Familial microscopic colitis. Can J Gastroenterol 2001; 15:341.</a></li><li><a class="nounderline abstract_t">Järnerot G, Hertervig E, Grännö C, et al. Familial occurrence of microscopic colitis: a report on five families. Scand J Gastroenterol 2001; 36:959.</a></li><li><a class="nounderline abstract_t">van Tilburg AJ, Lam HG, Seldenrijk CA, et al. Familial occurrence of collagenous colitis. A report of two families. J Clin Gastroenterol 1990; 12:279.</a></li><li><a class="nounderline abstract_t">Jackson BK. Are collagenous colitis and lymphocytic colitis distinct syndromes? Dig Dis 1995; 13:301.</a></li><li><a class="nounderline abstract_t">Olesen M, Eriksson S, Bohr J, et al. Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients. Gut 2004; 53:536.</a></li><li><a class="nounderline abstract_t">Fumery M, Kohut M, Gower-Rousseau C, et al. Incidence, Clinical Presentation, and Associated Factors of Microscopic Colitis in Northern France: A Population-Based Study. Dig Dis Sci 2016.</a></li><li><a class="nounderline abstract_t">Mellander MR, Ekbom A, Hultcrantz R, et al. Microscopic colitis: a descriptive clinical cohort study of 795 patients with collagenous and lymphocytic colitis. Scand J Gastroenterol 2016; 51:556.</a></li><li><a class="nounderline abstract_t">Kao KT, Pedraza BA, McClune AC, et al. Microscopic colitis: a large retrospective analysis from a health maintenance organization experience. World J Gastroenterol 2009; 15:3122.</a></li><li><a class="nounderline abstract_t">Koskela RM, Niemelä SE, Karttunen TJ, Lehtola JK. Clinical characteristics of collagenous and lymphocytic colitis. Scand J Gastroenterol 2004; 39:837.</a></li><li><a class="nounderline abstract_t">Kingsmore SF, Kingsmore DB, Hall BD, et al. Cooccurrence of collagenous colitis with seronegative spondyloarthropathy: report of a case and literature review. J Rheumatol 1993; 20:2153.</a></li><li><a class="nounderline abstract_t">Arora DS, Mahmood T, Wyatt JI. Lymphocytic venulitis: an unusual association with microscopic colitis. J Clin Pathol 1999; 52:303.</a></li><li><a class="nounderline abstract_t">Castellano VM, Muñoz MT, Colina F, et al. Collagenous gastrobulbitis and collagenous colitis. Case report and review of the literature. Scand J Gastroenterol 1999; 34:632.</a></li><li><a class="nounderline abstract_t">Koskela RM, Karttunen TJ, Niemelä SE, et al. Human leucocyte antigen and TNFalpha polymorphism association in microscopic colitis. Eur J Gastroenterol Hepatol 2008; 20:276.</a></li><li><a class="nounderline abstract_t">Fine KD, Do K, Schulte K, et al. High prevalence of celiac sprue-like HLA-DQ genes and enteropathy in patients with the microscopic colitis syndrome. Am J Gastroenterol 2000; 95:1974.</a></li><li><a class="nounderline abstract_t">Tagkalidis PP, Gibson PR, Bhathal PS. Microscopic colitis demonstrates a T helper cell type 1 mucosal cytokine profile. J Clin Pathol 2007; 60:382.</a></li><li><a class="nounderline abstract_t">Hamilton I, Sanders S, Hopwood D, Bouchier IA. Collagenous colitis associated with small intestinal villous atrophy. Gut 1986; 27:1394.</a></li><li><a class="nounderline abstract_t">O'Mahony S, Nawroz IM, Ferguson A. Coeliac disease and collagenous colitis. Postgrad Med J 1990; 66:238.</a></li><li><a class="nounderline abstract_t">Gillett HR, Freeman HJ. Prevalence of celiac disease in collagenous and lymphocytic colitis. Can J Gastroenterol 2000; 14:919.</a></li><li><a class="nounderline abstract_t">Barbato M, Viola F, Russo LL, et al. Microscopic and collagenous colitis in treated celiac disease due to food allergy? Gastroenterology 1999; 116:778.</a></li><li><a class="nounderline abstract_t">DuBois RN, Lazenby AJ, Yardley JH, et al. Lymphocytic enterocolitis in patients with 'refractory sprue'. JAMA 1989; 262:935.</a></li><li><a class="nounderline abstract_t">Greenson JK, Giardiello FM, Lazenby AJ, et al. Antireticulin antibodies in collagenous and lymphocytic (microscopic) colitis. Mod Pathol 1990; 3:259.</a></li><li><a class="nounderline abstract_t">McCashland TM, Donovan JP, Strobach RS, et al. Collagenous enterocolitis: a manifestation of gluten-sensitive enteropathy. J Clin Gastroenterol 1992; 15:45.</a></li><li><a class="nounderline abstract_t">Perisic VN, Kokai G, Pavlovic M. Coeliac disease and collagenous colitis. Ital J Gastroenterol 1992; 24:418.</a></li><li><a class="nounderline abstract_t">Freeman HJ. Collagenous colitis as the presenting feature of biopsy-defined celiac disease. J Clin Gastroenterol 2004; 38:664.</a></li><li><a class="nounderline abstract_t">Rönnblom A, Holmström T, Tanghöj H, et al. Celiac disease, collagenous sprue and microscopic colitis in IBD. Observations from a population-based cohort of IBD (ICURE). Scand J Gastroenterol 2015; 50:1234.</a></li><li><a class="nounderline abstract_t">Wickbom A, Bohr J, Nyhlin N, et al. Microscopic colitis in patients with ulcerative colitis or Crohn's disease: a retrospective observational study and review of the literature. Scand J Gastroenterol 2018; 53:410.</a></li><li><a class="nounderline abstract_t">Bergman D, Roelstraete B, Olén O, et al. Microscopic Colitis and Risk of Incident Acute Pancreatitis: A Nationwide Population-Based Matched Cohort Study. Am J Gastroenterol 2023; 118:2041.</a></li><li><a class="nounderline abstract_t">Christ AD, Meier R, Bauerfeind P, et al. [Simultaneous occurrence of lymphocytic gastritis and lymphocytic colitis with transition to collagenous colitis]. Schweiz Med Wochenschr 1993; 123:1487.</a></li><li><a class="nounderline abstract_t">Keszthelyi D, Penders J, Masclee AA, Pierik M. Is microscopic colitis a drug-induced disease? J Clin Gastroenterol 2012; 46:811.</a></li><li><a class="nounderline abstract_t">Masclee GM, Coloma PM, Kuipers EJ, Sturkenboom MC. Increased risk of microscopic colitis with use of proton pump inhibitors and non-steroidal anti-inflammatory drugs. Am J Gastroenterol 2015; 110:749.</a></li><li><a class="nounderline abstract_t">Verhaegh BP, de Vries F, Masclee AA, et al. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment Pharmacol Ther 2016; 43:1004.</a></li><li><a class="nounderline abstract_t">Bonderup OK, Fenger-Grøn M, Wigh T, et al. Drug exposure and risk of microscopic colitis: a nationwide Danish case-control study with 5751 cases. Inflamm Bowel Dis 2014; 20:1702.</a></li><li><a class="nounderline abstract_t">Bonderup OK, Nielsen GL, Dall M, et al. Significant association between the use of different proton pump inhibitors and microscopic colitis: a nationwide Danish case-control study. Aliment Pharmacol Ther 2018; 48:618.</a></li><li><a class="nounderline abstract_t">Ahmed M, Francis G. Pembrolizumab-Induced Microscopic Colitis. Am J Gastroenterol 2018; 113:629.</a></li><li><a class="nounderline abstract_t">D'sa FF, Fernandes EZ, Kesarkar SV, et al. Use of histamine-2 receptor antagonists and risk of inflammatory bowel diseases: A systematic review and meta-analysis of observational studies. J Clin Pharm Ther 2022; 47:1103.</a></li><li><a class="nounderline abstract_t">Beaugerie L, Pardi DS. Review article: drug-induced microscopic colitis - proposal for a scoring system and review of the literature. Aliment Pharmacol Ther 2005; 22:277.</a></li><li><a class="nounderline abstract_t">Baert F, Wouters K, D'Haens G, et al. Lymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis. Gut 1999; 45:375.</a></li><li><a class="nounderline abstract_t">Wilcox GM, Mattia AR. Microscopic colitis associated with omeprazole and esomeprazole exposure. J Clin Gastroenterol 2009; 43:551.</a></li><li><a class="nounderline abstract_t">Fernández-Bañares F, Salas A, Esteve M, et al. Collagenous and lymphocytic colitis. evaluation of clinical and histological features, response to treatment, and long-term follow-up. Am J Gastroenterol 2003; 98:340.</a></li><li><a class="nounderline abstract_t">Thomson RD, Lestina LS, Bensen SP, et al. Lansoprazole-associated microscopic colitis: a case series. Am J Gastroenterol 2002; 97:2908.</a></li><li><a class="nounderline abstract_t">Fernández-Bañares F, Esteve M, Espinós JC, et al. Drug consumption and the risk of microscopic colitis. Am J Gastroenterol 2007; 102:324.</a></li><li><a class="nounderline abstract_t">Giardiello FM, Hansen FC 3rd, Lazenby AJ, et al. Collagenous colitis in setting of nonsteroidal antiinflammatory drugs and antibiotics. Dig Dis Sci 1990; 35:257.</a></li><li><a class="nounderline abstract_t">Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993; 104:1832.</a></li><li><a class="nounderline abstract_t">Püspök A, Kiener HP, Oberhuber G. Clinical, endoscopic, and histologic spectrum of nonsteroidal anti-inflammatory drug-induced lesions in the colon. Dis Colon Rectum 2000; 43:685.</a></li><li><a class="nounderline abstract_t">Wilcox GM, Mattia A. Collagenous colitis associated with lansoprazole. J Clin Gastroenterol 2002; 34:164.</a></li><li><a class="nounderline abstract_t">Feurle GE, Bartz KO, Schmitt-Gräff A. Lymphocytic colitis, induced by ticlopidine. Z Gastroenterol 1999; 37:1105.</a></li><li><a class="nounderline abstract_t">Chande N, Driman DK. Microscopic colitis associated with lansoprazole: report of two cases and a review of the literature. Scand J Gastroenterol 2007; 42:530.</a></li><li><a class="nounderline abstract_t">Keszthelyi D, Jansen SV, Schouten GA, et al. Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study. Aliment Pharmacol Ther 2010; 32:1124.</a></li><li><a class="nounderline abstract_t">Münch A, Tysk C, Bohr J, et al. Smoking Status Influences Clinical Outcome in Collagenous Colitis. J Crohns Colitis 2016; 10:449.</a></li><li><a class="nounderline abstract_t">Verhaegh BPM, Pierik MJ, Goudkade D, et al. Early Life Exposure, Lifestyle, and Comorbidity as Risk Factors for Microscopic Colitis: A Case-Control Study. Inflamm Bowel Dis 2017; 23:1040.</a></li><li><a class="nounderline abstract_t">Wickbom A, Nyhlin N, Montgomery SM, et al. Family history, comorbidity, smoking and other risk factors in microscopic colitis: a case-control study. Eur J Gastroenterol Hepatol 2017; 29:587.</a></li><li><a class="nounderline abstract_t">Yen EF, Pokhrel B, Du H, et al. Current and past cigarette smoking significantly increase risk for microscopic colitis. Inflamm Bowel Dis 2012; 18:1835.</a></li><li><a class="nounderline abstract_t">Vigren L, Sjöberg K, Benoni C, et al. Is smoking a risk factor for collagenous colitis? Scand J Gastroenterol 2011; 46:1334.</a></li><li><a class="nounderline abstract_t">Fernández-Bañares F, de Sousa MR, Salas A, et al. Impact of current smoking on the clinical course of microscopic colitis. Inflamm Bowel Dis 2013; 19:1470.</a></li><li><a class="nounderline abstract_t">Jaruvongvanich V, Poonsombudlert K, Ungprasert P. Smoking and Risk of Microscopic Colitis: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2019; 25:672.</a></li><li><a class="nounderline abstract_t">Burke KE, Ananthakrishnan AN, Lochhead P, et al. Smoking is Associated with an Increased Risk of Microscopic Colitis: Results From Two Large Prospective Cohort Studies of US Women. J Crohns Colitis 2018; 12:559.</a></li><li><a class="nounderline abstract_t">Jessurun J, Yardley JH, Lee EL, et al. Microscopic and collagenous colitis: different names for the same condition? Gastroenterology 1986; 91:1583.</a></li><li><a class="nounderline abstract_t">Fernández-Bañares F, Esteve M, Farré C, et al. Predisposing HLA-DQ2 and HLA-DQ8 haplotypes of coeliac disease and associated enteropathy in microscopic colitis. Eur J Gastroenterol Hepatol 2005; 17:1333.</a></li><li><a class="nounderline abstract_t">Daum S, Foss HD, Schuppan D, et al. Synthesis of collagen I in collagenous sprue. Clin Gastroenterol Hepatol 2006; 4:1232.</a></li><li><a class="nounderline abstract_t">Aigner T, Neureiter D, Müller S, et al. Extracellular matrix composition and gene expression in collagenous colitis. Gastroenterology 1997; 113:136.</a></li><li><a class="nounderline abstract_t">Günther U, Schuppan D, Bauer M, et al. Fibrogenesis and fibrolysis in collagenous colitis. Patterns of procollagen types I and IV, matrix-metalloproteinase-1 and -13, and TIMP-1 gene expression. Am J Pathol 1999; 155:493.</a></li><li><a class="nounderline abstract_t">Ståhle-Bäckdahl M, Maim J, Veress B, et al. Increased presence of eosinophilic granulocytes expressing transforming growth factor-beta1 in collagenous colitis. Scand J Gastroenterol 2000; 35:742.</a></li><li><a class="nounderline abstract_t">Griga T, Tromm A, Schmiegel W, et al. Collagenous colitis: implications for the role of vascular endothelial growth factor in repair mechanisms. Eur J Gastroenterol Hepatol 2004; 16:397.</a></li><li><a class="nounderline abstract_t">Taha Y, Raab Y, Larsson A, et al. Vascular endothelial growth factor (VEGF)--a possible mediator of inflammation and mucosal permeability in patients with collagenous colitis. Dig Dis Sci 2004; 49:109.</a></li><li><a class="nounderline abstract_t">Andresen L, Jørgensen VL, Perner A, et al. Activation of nuclear factor kappaB in colonic mucosa from patients with collagenous and ulcerative colitis. Gut 2005; 54:503.</a></li><li><a class="nounderline abstract_t">Andersen T, Andersen JR, Tvede M, Franzmann MB. Collagenous colitis: are bacterial cytotoxins responsible? Am J Gastroenterol 1993; 88:375.</a></li><li><a class="nounderline abstract_t">Khan MA, Brunt EM, Longo WE, Presti ME. Persistent Clostridium difficile colitis: a possible etiology for the development of collagenous colitis. Dig Dis Sci 2000; 45:998.</a></li><li><a class="nounderline abstract_t">Treanor D, Gibbons D, O' Donoghue DP, Sheahan K. Pseudomembranes in collagenous colitis. Histopathology 2001; 38:83.</a></li><li><a class="nounderline abstract_t">Vesoulis Z, Lozanski G, Loiudice T. Synchronous occurrence of collagenous colitis and pseudomembranous colitis. Can J Gastroenterol 2000; 14:353.</a></li><li><a class="nounderline abstract_t">Bohr J, Nordfelth R, Järnerot G, Tysk C. Yersinia species in collagenous colitis: a serologic study. Scand J Gastroenterol 2002; 37:711.</a></li><li><a class="nounderline abstract_t">Narayani RI, Burton MP, Young GS. Resolution of collagenous colitis after treatment for Helicobacter pylori. Am J Gastroenterol 2002; 97:498.</a></li><li><a class="nounderline abstract_t">Tremaine WJ. Diagnosing collagenous colitis: does it make a difference? Eur J Gastroenterol Hepatol 1999; 11:477.</a></li><li><a class="nounderline abstract_t">Bürgel N, Bojarski C, Mankertz J, et al. Mechanisms of diarrhea in collagenous colitis. Gastroenterology 2002; 123:433.</a></li><li><a class="nounderline abstract_t">Bohr J, Järnerot G, Tysk C, et al. Effect of fasting on diarrhoea in collagenous colitis. Digestion 2002; 65:30.</a></li><li><a class="nounderline abstract_t">Ung KA, Gillberg R, Kilander A, Abrahamsson H. Role of bile acids and bile acid binding agents in patients with collagenous colitis. Gut 2000; 46:170.</a></li><li><a class="nounderline abstract_t">Zins BJ, Sandborn WJ, Tremaine WJ. Collagenous and lymphocytic colitis: subject review and therapeutic alternatives. Am J Gastroenterol 1995; 90:1394.</a></li><li><a class="nounderline abstract_t">Münch A, Langner C. Microscopic colitis: clinical and pathologic perspectives. Clin Gastroenterol Hepatol 2015; 13:228.</a></li><li><a class="nounderline abstract_t">Abboud R, Pardi DS, Tremaine WJ, et al. Symptomatic overlap between microscopic colitis and irritable bowel syndrome: a prospective study. Inflamm Bowel Dis 2013; 19:550.</a></li><li><a class="nounderline abstract_t">Bjørnbak C, Engel PJ, Nielsen PL, Munck LK. Microscopic colitis: clinical findings, topography and persistence of histopathological subgroups. Aliment Pharmacol Ther 2011; 34:1225.</a></li><li><a class="nounderline abstract_t">Hjortswang H, Tysk C, Bohr J, et al. Health-related quality of life is impaired in active collagenous colitis. Dig Liver Dis 2011; 43:102.</a></li><li><a class="nounderline abstract_t">Giardiello FM, Bayless TM, Jessurun J, et al. Collagenous colitis: physiologic and histopathologic studies in seven patients. Ann Intern Med 1987; 106:46.</a></li><li><a class="nounderline abstract_t">Sylwestrowicz T, Kelly JK, Hwang WS, Shaffer EA. Collagenous colitis and microscopic colitis: the watery diarrhea-colitis syndrome. Am J Gastroenterol 1989; 84:763.</a></li><li><a class="nounderline abstract_t">Roth B, Gustafsson RJ, Ohlsson B. Auto-antibodies and their association with clinical findings in women diagnosed with microscopic colitis. PLoS One 2013; 8:e66088.</a></li><li><a class="nounderline abstract_t">Lettesjö H, Hansson T, Peterson C, et al. Detection of inflammatory markers in stools from patients with irritable bowel syndrome and collagenous colitis. Scand J Gastroenterol 2006; 41:54.</a></li><li><a class="nounderline abstract_t">Wildt S, Nordgaard-Lassen I, Bendtsen F, Rumessen JJ. Metabolic and inflammatory faecal markers in collagenous colitis. Eur J Gastroenterol Hepatol 2007; 19:567.</a></li><li><a class="nounderline abstract_t">Münch A, Aust D, Bohr J, et al. Microscopic colitis: Current status, present and future challenges: statements of the European Microscopic Colitis Group. J Crohns Colitis 2012; 6:932.</a></li><li><a class="nounderline abstract_t">Kamp EJ, Kane JS, Ford AC. Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2016; 14:659.</a></li><li><a class="nounderline abstract_t">Guagnozzi D, Arias Á, Lucendo AJ. Systematic review with meta-analysis: diagnostic overlap of microscopic colitis and functional bowel disorders. Aliment Pharmacol Ther 2016; 43:851.</a></li><li><a class="nounderline abstract_t">von Arnim U, Wex T, Ganzert C, et al. Fecal calprotectin: a marker for clinical differentiation of microscopic colitis and irritable bowel syndrome. Clin Exp Gastroenterol 2016; 9:97.</a></li><li><a class="nounderline abstract_t">Batista L, Ruiz L, Ferrer C, et al. Usefulness of fecal calprotectin as a biomarker of microscopic colitis in a cohort of patients with chronic watery diarrhoea of functional characteristics. Dig Liver Dis 2019; 51:1646.</a></li><li><a class="nounderline abstract_t">Sherman A, Ackert JJ, Rajapaksa R, et al. Fractured colon: an endoscopically distinctive lesion associated with colonic perforation following colonoscopy in patients with collagenous colitis. J Clin Gastroenterol 2004; 38:341.</a></li><li><a class="nounderline abstract_t">Allende DS, Taylor SL, Bronner MP. Colonic perforation as a complication of collagenous colitis in a series of 12 patients. Am J Gastroenterol 2008; 103:2598.</a></li><li><a class="nounderline abstract_t">Hussain Z, Kelly S, Clarke A, et al. Colonic perforation in collagenous colitis: a systematic review of a rare complication and guidance on management. Surg Endosc 2010; 24:2930.</a></li><li><a class="nounderline abstract_t">Moore M, Coleman HG, Allen PB, Loughrey MB. Microscopic colitis: a population-based case series over a 9-year period in Northern Ireland. Colorectal Dis 2018; 20:1020.</a></li><li><a class="nounderline abstract_t">Macaigne G, Lahmek P, Locher C, et al. Over 90% of cases of Microscopic Colitis can be diagnosed by performing a short colonoscopy. Clin Res Hepatol Gastroenterol 2017; 41:333.</a></li><li><a class="nounderline abstract_t">Davidson S, Sjöberg K, Engel PJH, et al. Microscopic colitis in Denmark and Sweden: incidence, putative risk factors, histological assessment and endoscopic activity. Scand J Gastroenterol 2018; 53:818.</a></li><li><a class="nounderline abstract_t">Suzuki G, Mellander MR, Suzuki A, et al. Usefulness of colonoscopic examination with indigo carmine in diagnosing microscopic colitis. Endoscopy 2011; 43:1100.</a></li><li><a class="nounderline abstract_t">Ohmiya N, Horiguchi N, Tahara T, et al. Usefulness of confocal laser endomicroscopy to diagnose ulcerative colitis-associated neoplasia. Dig Endosc 2017; 29:626.</a></li><li><a class="nounderline abstract_t">Park HS, Han DS, Ro YO, et al. Does lymphocytic colitis always present with normal endoscopic findings? Gut Liver 2015; 9:197.</a></li><li><a class="nounderline abstract_t">Koulaouzidis A, Yung DE, Nemeth A, et al. Macroscopic findings in collagenous colitis: a multi-center, retrospective, observational cohort study. Ann Gastroenterol 2017; 30:309.</a></li><li><a class="nounderline abstract_t">Marlicz W, Skonieczna-Żydecka K, Yung DE, et al. Endoscopic findings and colonic perforation in microscopic colitis: A systematic review. Dig Liver Dis 2017; 49:1073.</a></li><li><a class="nounderline abstract_t">Chang F, Deere H, Vu C. Atypical forms of microscopic colitis: morphological features and review of the literature. Adv Anat Pathol 2005; 12:203.</a></li><li><a class="nounderline abstract_t">Sonnenberg A, Genta RM. Lymphocytic and collagenous colitis: epidemiologic differences and similarities. Dig Dis Sci 2013; 58:2970.</a></li><li><a class="nounderline abstract_t">Chandratre S, Bramble MG, Cooke WM, Jones RA. Simultaneous occurrence of collagenous colitis and Crohn's disease. Digestion 1987; 36:55.</a></li><li><a class="nounderline abstract_t">Chutkan R, Sternthal M, Janowitz HD. A family with collagenous colitis, ulcerative colitis, and Crohn's disease. Am J Gastroenterol 2000; 95:3640.</a></li><li><a class="nounderline abstract_t">Goldblum JR, Wang N. Lymphocytic and collagenous colitis as possible patterns of Crohn's colitis. Am J Surg Pathol 2000; 24:755.</a></li><li><a class="nounderline abstract_t">Melato M, Perazza L, Buri L. Collagenous colitis and Crohn's disease: unrelated? Ital J Gastroenterol 1996; 28:406.</a></li><li><a class="nounderline abstract_t">Goldstein NS, Gyorfi T. Focal lymphocytic colitis and collagenous colitis: patterns of Crohn's colitis? Am J Surg Pathol 1999; 23:1075.</a></li><li><a class="nounderline abstract_t">Rezaie A, Buresi M, Lembo A, et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am J Gastroenterol 2017; 112:775.</a></li><li><a class="nounderline abstract_t">Ratuapli SK, Ellington TG, O'Neill MT, et al. Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. Am J Gastroenterol 2012; 107:730.</a></li><li><a class="nounderline abstract_t">Hjortswang H, Tysk C, Bohr J, et al. Defining clinical criteria for clinical remission and disease activity in collagenous colitis. Inflamm Bowel Dis 2009; 15:1875.</a></li><li><a class="nounderline abstract_t">Beaugerie L, Pardi DS. Patients with drug-induced microscopic colitis should not be included in controlled trials assessing the efficacy of anti-inflammatory drugs in microscopic colitis. Gastroenterology 2009; 137:1535.</a></li><li><a class="nounderline abstract_t">Kingham JG. Microscopic colitis. Gut 1991; 32:234.</a></li><li><a class="nounderline abstract_t">Miehlke S, Aust D, Mihaly E, et al. Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis. Gastroenterology 2018; 155:1795.</a></li><li><a class="nounderline abstract_t">Chande N, Al Yatama N, Bhanji T, et al. Interventions for treating lymphocytic colitis. Cochrane Database Syst Rev 2017; 7:CD006096.</a></li><li><a class="nounderline abstract_t">Kafil TS, Nguyen TM, Patton PH, et al. Interventions for treating collagenous colitis. Cochrane Database Syst Rev 2017; 11:CD003575.</a></li><li><a class="nounderline abstract_t">Sebastian S, Wilhelm A, Jessica L, et al. Budesonide treatment for microscopic colitis: systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2019; 31:919.</a></li><li><a class="nounderline abstract_t">Münch A, Mihaly E, Nagy F, et al. Budesonide as induction therapy for incomplete microscopic colitis: A randomised, placebo-controlled multicentre trial. United European Gastroenterol J 2021; 9:837.</a></li><li><a class="nounderline abstract_t">Miehlke S, Madisch A, Voss C, et al. Long-term follow-up of collagenous colitis after induction of clinical remission with budesonide. Aliment Pharmacol Ther 2005; 22:1115.</a></li><li><a class="nounderline abstract_t">Baert F, Schmit A, D'Haens G, et al. Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up. Gastroenterology 2002; 122:20.</a></li><li><a class="nounderline abstract_t">Miehlke S, Heymer P, Bethke B, et al. Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology 2002; 123:978.</a></li><li><a class="nounderline abstract_t">Bonderup OK, Hansen JB, Birket-Smith L, et al. Budesonide treatment of collagenous colitis: a randomised, double blind, placebo controlled trial with morphometric analysis. Gut 2003; 52:248.</a></li><li><a class="nounderline abstract_t">Madisch A, Heymer P, Voss C, et al. Oral budesonide therapy improves quality of life in patients with collagenous colitis. Int J Colorectal Dis 2005; 20:312.</a></li><li><a class="nounderline abstract_t">Miehlke S, Madisch A, Kupcinskas L, et al. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis. Gastroenterology 2014; 146:1222.</a></li><li><a class="nounderline abstract_t">Stewart MJ, Seow CH, Storr MA. Prednisolone and budesonide for short- and long-term treatment of microscopic colitis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2011; 9:881.</a></li><li><a class="nounderline abstract_t">Miehlke S, Madisch A, Karimi D, et al. Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study. Gastroenterology 2009; 136:2092.</a></li><li><a class="nounderline abstract_t">Munck LK, Kjeldsen J, Philipsen E, Fischer Hansen B. Incomplete remission with short-term prednisolone treatment in collagenous colitis: a randomized study. Scand J Gastroenterol 2003; 38:606.</a></li><li><a class="nounderline abstract_t">Zeroogian JM, Chopra S. Collagenous colitis and lymphocytic colitis. Annu Rev Med 1994; 45:105.</a></li><li><a class="nounderline abstract_t">Sloth H, Bisgaard C, Grove A. Collagenous colitis: a prospective trial of prednisolone in six patients. J Intern Med 1991; 229:443.</a></li><li><a class="nounderline abstract_t">Gentile NM, Abdalla AA, Khanna S, et al. Outcomes of patients with microscopic colitis treated with corticosteroids: a population-based study. Am J Gastroenterol 2013; 108:256.</a></li><li><a class="nounderline abstract_t">Calabrese C, Fabbri A, Areni A, et al. Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial. J Gastroenterol Hepatol 2007; 22:809.</a></li><li><a class="nounderline abstract_t">Laing AW, Pardi DS, Loftus EV Jr, et al. Microscopic colitis is not associated with cholecystectomy or appendectomy. Inflamm Bowel Dis 2006; 12:708.</a></li><li><a class="nounderline abstract_t">Fine KD, Lee EL. Efficacy of open-label bismuth subsalicylate for the treatment of microscopic colitis. Gastroenterology 1998; 114:29.</a></li><li><a class="nounderline abstract_t">Fine K, Ogunji F, Lee E, et al. Randomized, double-blind, placebo-controlled trial of bismuth subsalicylate for microscopic colitis (abstract). Gastroenterology 1999; 116:880.</a></li><li><a class="nounderline abstract_t">Aziz M, Haghbin H, Khan RS, et al. Celiac Disease Is Associated with Microscopic Colitis in Refractory Cases in Adults: A Systematic Review and Meta-Analysis of Observational Studies. Dig Dis Sci 2022; 67:3529.</a></li><li><a class="nounderline abstract_t">Limsui D, Pardi DS, Camilleri M, et al. Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis 2007; 13:175.</a></li><li><a class="nounderline abstract_t">Madisch A, Bethke B, Stolte M, Miehlke S. Is there an association of microscopic colitis and irritable bowel syndrome--a subgroup analysis of placebo-controlled trials. World J Gastroenterol 2005; 11:6409.</a></li><li><a class="nounderline abstract_t">Pardi DS, Loftus EV Jr, Tremaine WJ, Sandborn WJ. Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine. Gastroenterology 2001; 120:1483.</a></li><li><a class="nounderline abstract_t">Esteve M, Mahadevan U, Sainz E, et al. Efficacy of anti-TNF therapies in refractory severe microscopic colitis. J Crohns Colitis 2011; 5:612.</a></li><li><a class="nounderline abstract_t">Münch A, Ignatova S, Ström M. Adalimumab in budesonide and methotrexate refractory collagenous colitis. Scand J Gastroenterol 2012; 47:59.</a></li><li><a class="nounderline abstract_t">Pola S, Fahmy M, Evans E, et al. Successful use of infliximab in the treatment of corticosteroid dependent collagenous colitis. Am J Gastroenterol 2013; 108:857.</a></li><li><a class="nounderline abstract_t">Münch A, Fernandez-Banares F, Munck LK. Azathioprine and mercaptopurine in the management of patients with chronic, active microscopic colitis. Aliment Pharmacol Ther 2013; 37:795.</a></li><li><a class="nounderline abstract_t">Jennings JJ, Charabaty A. Vedolizumab-Induced Remission in 3 Patients With Refractory Microscopic Colitis: A Tertiary Care Center Case Series. Inflamm Bowel Dis 2019; 25:e97.</a></li><li><a class="nounderline abstract_t">Rivière P, Münch A, Michetti P, et al. Vedolizumab in Refractory Microscopic Colitis: An International Case Series. J Crohns Colitis 2019; 13:337.</a></li><li><a class="nounderline abstract_t">Wenzel AA, Strople J, Melin-Aldana H, Brown JB. Vedolizumab for the Induction of Remission in Treatment-refractory Microscopic Colitis in a Pediatric Patient. J Pediatr Gastroenterol Nutr 2020; 71:e47.</a></li><li><a class="nounderline abstract_t">Cushing KC, Mino-Kenudson M, Garber J, et al. Vedolizumab as a Novel Treatment for Refractory Collagenous Colitis: A Case Report. Am J Gastroenterol 2018; 113:632.</a></li><li><a class="nounderline abstract_t">Casper M, Zimmer V, Hübschen U, Lammert F. Vedolizumab for refractory collagenous colitis: Another piece of the puzzle. Dig Liver Dis 2018; 50:1099.</a></li><li><a class="nounderline abstract_t">Bowling TE, Price AB, al-Adnani M, et al. Interchange between collagenous and lymphocytic colitis in severe disease with autoimmune associations requiring colectomy: a case report. Gut 1996; 38:788.</a></li><li><a class="nounderline abstract_t">Williams RA, Gelfand DV. Total proctocolectomy and ileal pouch anal anastomosis to successfully treat a patient with collagenous colitis. Am J Gastroenterol 2000; 95:2147.</a></li><li><a class="nounderline abstract_t">Järnerot G, Tysk C, Bohr J, Eriksson S. Collagenous colitis and fecal stream diversion. Gastroenterology 1995; 109:449.</a></li><li><a class="nounderline abstract_t">Riaz AA, Pitt J, Stirling RW, et al. Restorative proctocolectomy for collagenous colitis. J R Soc Med 2000; 93:261.</a></li><li><a class="nounderline abstract_t">S Miehlke; D. Oral once daily budesonide granules rapidly induce clinical remission in Lymphocytic Colitis: A double-blind, double-dummy, multi-centre, randomized trial. Journal of Crohn's and Colitis 2018; 12:S491.</a></li><li><a class="nounderline abstract_t">Münch A, Bohr J, Vigren L, et al. Lack of effect of methotrexate in budesonide-refractory collagenous colitis. Clin Exp Gastroenterol 2013; 6:149.</a></li><li><a class="nounderline abstract_t">Fisher NC, Tutt A, Sim E, et al. Collagenous colitis responsive to octreotide therapy. J Clin Gastroenterol 1996; 23:300.</a></li><li><a class="nounderline abstract_t">Scheidler MD, Meiselman M. Use of verapamil for the symptomatic treatment of microscopic colitis. J Clin Gastroenterol 2001; 32:351.</a></li><li><a class="nounderline abstract_t">Madisch A, Miehlke S, Eichele O, et al. Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial. Int J Colorectal Dis 2007; 22:1445.</a></li><li><a class="nounderline abstract_t">Wildt S, Munck LK, Vinter-Jensen L, et al. Probiotic treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial with Lactobacillus acidophilus and Bifidobacterium animalis subsp. Lactis. Inflamm Bowel Dis 2006; 12:395.</a></li><li><a class="nounderline abstract_t">Miehlke S, Acosta MB, Bouma G, et al. Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinician. J Gastroenterol Hepatol 2018.</a></li><li><a class="nounderline abstract_t">Miehlke S, Madisch A, Bethke B, et al. Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2008; 135:1510.</a></li><li><a class="nounderline abstract_t">Bonderup OK, Hansen JB, Teglbjaerg PS, et al. Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial. Gut 2009; 58:68.</a></li><li><a class="nounderline abstract_t">Münch A, Bohr J, Miehlke S, et al. Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial. Gut 2016; 65:47.</a></li><li><a class="nounderline abstract_t">Wildt S, Munck LK, Becker S, et al. Risk of osteoporosis in microscopic colitis. Postgrad Med 2018; 130:348.</a></li><li><a class="nounderline abstract_t">Bonderup OK, Folkersen BH, Gjersøe P, Teglbjaerg PS. Collagenous colitis: a long-term follow-up study. Eur J Gastroenterol Hepatol 1999; 11:493.</a></li><li><a class="nounderline abstract_t">Madisch A, Miehlke S, Lindner M, et al. Clinical course of collagenous colitis over a period of 10 years. Z Gastroenterol 2006; 44:971.</a></li><li><a class="nounderline abstract_t">Mullhaupt B, Güller U, Anabitarte M, et al. Lymphocytic colitis: clinical presentation and long term course. Gut 1998; 43:629.</a></li></ol></div><div id="topicVersionRevision">Topic 4071 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7350049" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Chronic diarrhea of unknown origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2912870" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Lymphocytic ("microscopic") colitis: a comparative histopathologic study with particular reference to collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26584605" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : American Gastroenterological Association Institute Guideline on the Medical Management of Microscopic Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32819215" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : European guidelines on microscopic colitis: United European Gastroenterology (UEG) and European Microscopic Colitis Group (EMCG) statements and recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7590436" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Collagenous colitis in Orebro, Sweden, an epidemiological study 1984-1993.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14960513" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Microscopic colitis: a common diarrhoeal disease. An epidemiological study in Orebro, Sweden, 1993-1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022639" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Incidence of collagenous and lymphocytic colitis: a 5-year population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12018911" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Collagenous and lymphocytic colitis in Iceland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17135309" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18166476" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Microscopic colitis-defining incidence rates and risk factors: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23945183" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Stable incidence of collagenous colitis and lymphocytic colitis inÖrebro, Sweden, 1999-2008: a continuous epidemiologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25645623" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The epidemiology of microscopic colitis: a 10-year pathology-based nationwide Danish cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25623658" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Incidence, prevalence, and temporal trends of microscopic colitis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26148269" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Erratum: Incidence, Prevalence, and Temporal Trends of Microscopic Colitis: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9038667" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8095037" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Collagenous colitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8335221" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Collagenous colitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18186560" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clear cell colitis: a form of microscopic colitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7615277" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Microscopic colitis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1451972" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Subepithelial collagen table thickness in colon specimens from patients with microscopic colitis and collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8809245" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The new colitides, Collagenous, lymphocytic, and diversion colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3610134" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Chronic colitis with thickening of the subepithelial collagen layer (collagenous colitis): histopathologic findings in 15 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1361906" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Sequential histologic evaluations in collagenous colitis. Correlations with disease behavior and sampling strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2394435" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pitfalls in the diagnosis of collagenous colitis: experience with 75 cases from a registry of collagenous colitis at the Johns Hopkins Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3140474" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Collagenous colitis: histologic, morphometric, immunohistochemical and ultrastructural studies. Report of 21 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7731251" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Collagenous colitis: mucosal biopsies and association with fecal leukocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11381303" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Familial microscopic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11521987" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Familial occurrence of microscopic colitis: a report on five families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2362097" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Familial occurrence of collagenous colitis. A report of two families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8542665" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Are collagenous colitis and lymphocytic colitis distinct syndromes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15016748" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27659673" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Incidence, Clinical Presentation, and Associated Factors of Microscopic Colitis in Northern France: A Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679722" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Microscopic colitis: a descriptive clinical cohort study of 795 patients with collagenous and lymphocytic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19575491" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Microscopic colitis: a large retrospective analysis from a health maintenance organization experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15513381" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clinical characteristics of collagenous and lymphocytic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8014948" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cooccurrence of collagenous colitis with seronegative spondyloarthropathy: report of a case and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10474525" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Lymphocytic venulitis: an unusual association with microscopic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10440616" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Collagenous gastrobulbitis and collagenous colitis. Case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18334870" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Human leucocyte antigen and TNFalpha polymorphism association in microscopic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10950045" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : High prevalence of celiac sprue-like HLA-DQ genes and enteropathy in patients with the microscopic colitis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16775121" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Microscopic colitis demonstrates a T helper cell type 1 mucosal cytokine profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3792923" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Collagenous colitis associated with small intestinal villous atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2362896" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Coeliac disease and collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11125181" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prevalence of celiac disease in collagenous and lymphocytic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10029639" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Microscopic and collagenous colitis in treated celiac disease due to food allergy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2754795" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Lymphocytic enterocolitis in patients with 'refractory sprue'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2362935" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Antireticulin antibodies in collagenous and lymphocytic (microscopic) colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1500661" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Collagenous enterocolitis: a manifestation of gluten-sensitive enteropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1392026" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Coeliac disease and collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15319648" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Collagenous colitis as the presenting feature of biopsy-defined celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25921772" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Celiac disease, collagenous sprue and microscopic colitis in IBD. Observations from a population-based cohort of IBD (ICURE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29546806" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Microscopic colitis in patients with ulcerative colitis or Crohn's disease: a retrospective observational study and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37171015" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Microscopic Colitis and Risk of Incident Acute Pancreatitis: A Nationwide Population-Based Matched Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8367708" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : [Simultaneous occurrence of lymphocytic gastritis and lymphocytic colitis with transition to collagenous colitis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23060216" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Is microscopic colitis a drug-induced disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25916221" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Increased risk of microscopic colitis with use of proton pump inhibitors and non-steroidal anti-inflammatory drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26956016" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25153503" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Drug exposure and risk of microscopic colitis: a nationwide Danish case-control study with 5751 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30039564" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Significant association between the use of different proton pump inhibitors and microscopic colitis: a nationwide Danish case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29610496" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Pembrolizumab-Induced Microscopic Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35403222" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Use of histamine-2 receptor antagonists and risk of inflammatory bowel diseases: A systematic review and meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16097993" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Review article: drug-induced microscopic colitis - proposal for a scoring system and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10446105" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Lymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19142168" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Microscopic colitis associated with omeprazole and esomeprazole exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12591052" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Collagenous and lymphocytic colitis. evaluation of clinical and histological features, response to treatment, and long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12425567" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Lansoprazole-associated microscopic colitis: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17100977" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Drug consumption and the risk of microscopic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2302984" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Collagenous colitis in setting of nonsteroidal antiinflammatory drugs and antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8500743" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10826432" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Clinical, endoscopic, and histologic spectrum of nonsteroidal anti-inflammatory drug-induced lesions in the colon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11782613" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Collagenous colitis associated with lansoprazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10604225" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Lymphocytic colitis, induced by ticlopidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17454866" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Microscopic colitis associated with lansoprazole: report of two cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21039674" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26721941" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Smoking Status Influences Clinical Outcome in Collagenous Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28471835" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Early Life Exposure, Lifestyle, and Comorbidity as Risk Factors for Microscopic Colitis: A Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28350750" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Family history, comorbidity, smoking and other risk factors in microscopic colitis: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22147506" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Current and past cigarette smoking significantly increase risk for microscopic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21854096" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Is smoking a risk factor for collagenous colitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23552765" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Impact of current smoking on the clinical course of microscopic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30869794" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Smoking and Risk of Microscopic Colitis: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29370359" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Smoking is Associated with an Increased Risk of Microscopic Colitis: Results From Two Large Prospective Cohort Studies of US Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3770384" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Microscopic and collagenous colitis: different names for the same condition?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16292086" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Predisposing HLA-DQ2 and HLA-DQ8 haplotypes of coeliac disease and associated enteropathy in microscopic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16979955" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Synthesis of collagen I in collagenous sprue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207271" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Extracellular matrix composition and gene expression in collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10433942" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Fibrogenesis and fibrolysis in collagenous colitis. Patterns of procollagen types I and IV, matrix-metalloproteinase-1 and -13, and TIMP-1 gene expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10972179" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Increased presence of eosinophilic granulocytes expressing transforming growth factor-beta1 in collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15028972" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Collagenous colitis: implications for the role of vascular endothelial growth factor in repair mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14992444" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Vascular endothelial growth factor (VEGF)--a possible mediator of inflammation and mucosal permeability in patients with collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15753535" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Activation of nuclear factor kappaB in colonic mucosa from patients with collagenous and ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8438843" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Collagenous colitis: are bacterial cytotoxins responsible?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10795766" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Persistent Clostridium difficile colitis: a possible etiology for the development of collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11210854" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Pseudomembranes in collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10799091" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Synchronous occurrence of collagenous colitis and pseudomembranous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12126251" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Yersinia species in collagenous colitis: a serologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11866305" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Resolution of collagenous colitis after treatment for Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10755248" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Diagnosing collagenous colitis: does it make a difference?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12145796" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Mechanisms of diarrhea in collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11961340" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Effect of fasting on diarrhoea in collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10644309" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Role of bile acids and bile acid binding agents in patients with collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7661156" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Collagenous and lymphocytic colitis: subject review and therapeutic alternatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24407107" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Microscopic colitis: clinical and pathologic perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23380937" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Symptomatic overlap between microscopic colitis and irritable bowel syndrome: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21967618" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Microscopic colitis: clinical findings, topography and persistence of histopathological subgroups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20638918" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Health-related quality of life is impaired in active collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3789577" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Collagenous colitis: physiologic and histopathologic studies in seven patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2741886" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Collagenous colitis and microscopic colitis: the watery diarrhea-colitis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23776613" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Auto-antibodies and their association with clinical findings in women diagnosed with microscopic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16373277" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Detection of inflammatory markers in stools from patients with irritable bowel syndrome and collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17556903" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Metabolic and inflammatory faecal markers in collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22704658" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Microscopic colitis: Current status, present and future challenges: statements of the European Microscopic Colitis Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26453949" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26913568" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Systematic review with meta-analysis: diagnostic overlap of microscopic colitis and functional bowel disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27147826" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Fecal calprotectin: a marker for clinical differentiation of microscopic colitis and irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31383457" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Usefulness of fecal calprotectin as a biomarker of microscopic colitis in a cohort of patients with chronic watery diarrhoea of functional characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15087693" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Fractured colon: an endoscopically distinctive lesion associated with colonic perforation following colonoscopy in patients with collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18702648" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Colonic perforation as a complication of collagenous colitis in a series of 12 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20464421" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Colonic perforation in collagenous colitis: a systematic review of a rare complication and guidance on management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29742325" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Microscopic colitis: a population-based case series over a 9-year period in Northern Ireland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28215538" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Over 90% of cases of Microscopic Colitis can be diagnosed by performing a short colonoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29852792" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Microscopic colitis in Denmark and Sweden: incidence, putative risk factors, histological assessment and endoscopic activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22057822" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Usefulness of colonoscopic examination with indigo carmine in diagnosing microscopic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28244237" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Usefulness of confocal laser endomicroscopy to diagnose ulcerative colitis-associated neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25167800" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Does lymphocytic colitis always present with normal endoscopic findings?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28469361" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Macroscopic findings in collagenous colitis: a multi-center, retrospective, observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28847471" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Endoscopic findings and colonic perforation in microscopic colitis: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16096382" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Atypical forms of microscopic colitis: morphological features and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23709158" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Lymphocytic and collagenous colitis: epidemiologic differences and similarities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3556805" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Simultaneous occurrence of collagenous colitis and Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11151908" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : A family with collagenous colitis, ulcerative colitis, and Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10800997" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Lymphocytic and collagenous colitis as possible patterns of Crohn's colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8937945" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Collagenous colitis and Crohn's disease: unrelated?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10478667" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Focal lymphocytic colitis and collagenous colitis: patterns of Crohn's colitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28323273" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22334250" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19504614" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Defining clinical criteria for clinical remission and disease activity in collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19717133" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Patients with drug-induced microscopic colitis should not be included in controlled trials assessing the efficacy of anti-inflammatory drugs in microscopic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2013415" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Microscopic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30195447" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28702956" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Interventions for treating lymphocytic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29127772" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Interventions for treating collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31211724" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Budesonide treatment for microscopic colitis: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34414678" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Budesonide as induction therapy for incomplete microscopic colitis: A randomised, placebo-controlled multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16305725" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Long-term follow-up of collagenous colitis after induction of clinical remission with budesonide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11781276" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12360457" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12524408" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Budesonide treatment of collagenous colitis: a randomised, double blind, placebo controlled trial with morphometric analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15549326" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Oral budesonide therapy improves quality of life in patients with collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24440672" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21699817" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Prednisolone and budesonide for short- and long-term treatment of microscopic colitis: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19303012" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12825868" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Incomplete remission with short-term prednisolone treatment in collagenous colitis: a randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8198370" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Collagenous colitis and lymphocytic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2040870" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Collagenous colitis: a prospective trial of prednisolone in six patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23295275" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Outcomes of patients with microscopic colitis treated with corticosteroids: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17565633" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16917225" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Microscopic colitis is not associated with cholecystectomy or appendectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9428215" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Efficacy of open-label bismuth subsalicylate for the treatment of microscopic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Randomized, double-blind, placebo-controlled trial of bismuth subsalicylate for microscopic colitis (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34448981" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Celiac Disease Is Associated with Microscopic Colitis in Refractory Cases in Adults: A Systematic Review and Meta-Analysis of Observational Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17206699" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Symptomatic overlap between irritable bowel syndrome and microscopic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16425407" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Is there an association of microscopic colitis and irritable bowel syndrome--a subgroup analysis of placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11313319" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22115383" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Efficacy of anti-TNF therapies in refractory severe microscopic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22149977" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Adalimumab in budesonide and methotrexate refractory collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23644970" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Successful use of infliximab in the treatment of corticosteroid dependent collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23432370" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Azathioprine and mercaptopurine in the management of patients with chronic, active microscopic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30889247" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Vedolizumab-Induced Remission in 3 Patients With Refractory Microscopic Colitis: A Tertiary Care Center Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30329034" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Vedolizumab in Refractory Microscopic Colitis: An International Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32304548" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Vedolizumab for the Induction of Remission in Treatment-refractory Microscopic Colitis in a Pediatric Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29610507" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Vedolizumab as a Novel Treatment for Refractory Collagenous Colitis: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30115575" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Vedolizumab for refractory collagenous colitis: Another piece of the puzzle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8707130" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Interchange between collagenous and lymphocytic colitis in severe disease with autoimmune associations requiring colectomy: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10950095" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Total proctocolectomy and ileal pouch anal anastomosis to successfully treat a patient with collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7615194" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Collagenous colitis and fecal stream diversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10884773" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Restorative proctocolectomy for collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Oral once daily budesonide granules rapidly induce clinical remission in Lymphocytic Colitis: A double-blind, double-dummy, multi-centre, randomized trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24039441" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Lack of effect of methotrexate in budesonide-refractory collagenous colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8957735" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Collagenous colitis responsive to octreotide therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11276283" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Use of verapamil for the symptomatic treatment of microscopic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17764013" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16670529" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Probiotic treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial with Lactobacillus acidophilus and Bifidobacterium animalis subsp. Lactis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29603368" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinician.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18926826" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18669576" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25425655" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29460653" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Risk of osteoporosis in microscopic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10755251" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Collagenous colitis: a long-term follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16981069" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Clinical course of collagenous colitis over a period of 10 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9824342" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Lymphocytic colitis: clinical presentation and long term course.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
